跳至主要内容
临床试验/NCT05744076
NCT05744076进行中(未招募)不适用

Analysis of Circulating Exosomes in Melanoma Patients

Centre Hospitalier Universitaire de Besancon1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2019年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
150
试验地点
1
主要终点
Quantification of circulating exosomes

研究概览

简要总结

The hypothesis is that PD-L1[Programmed Death-Ligand 1] labeling in exosomes could be a biomarker of disease progression in melanoma. The rate of circulating exosomes, their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients. In this study, blood samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and associated clinical data are reused.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Melanoma patients admitted in Besançon University Hospital
  • exigible for immunotherapy such as anti PD-L1/PD-1
  • Age ≥18 years
  • Affiliation to a social security system,

排除标准

  • Minor patients
  • Patients who have expressed their opposition to the reuse of their data and biological samples

结局指标

主要结局

Quantification of circulating exosomes

时间窗: Day 1

Dosage of proteic biomarkers in circulating exosomes, plasma and tumor tissues. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation

次要结局

  • Other proteins detection(Day 1)
  • PDL1 marking(Day 1)
  • Determine whether the initial exosome concentration (at T0) is associated with a response to treatment.(Day 1)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Analysis of Circulating Exosomes in Melanoma Patients | 临床试验